Navigation Links
Ortho-McNeil initiates first-of-its-kind skin infection registry
Date:8/6/2008

Raritan, NJ, August 6, 2008 The nation's first, prospective registry of complicated skin and soft tissue infections (cSSTIs), known as SSTIR (the Skin and Soft Tissue Infection Hospital Registry), has begun enrolling patients. The SSTIR, plans to enroll more than 1,200 hospitalized patients by the end of this year, and is designed to better understand treatment patterns and provide data to help improve patient outcomes. The registry is sponsored by Ortho-McNeil, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

More than 50 hospitals nationwide will participate in this prospective, multi-center registry, which will comprehensively characterize the four major types of cSSTIs: diabetic foot infections, surgical site infections, deep soft tissue abscesses and cellulitis (an infection of tissue under the skin). In addition, the study will observe patient management in the hospital setting, including selection and timing of antibiotic treatment, changes in treatment regimen, outcomes, and economic impact.

"Physicians are treating more and more patients with complicated skin infections in hospitals across the U.S., and the emergence of resistant pathogens has made the situation even more complex," said Susan Nicholson, M.D., Therapeutic Area Leader, Internal Medicine, Ortho-McNeil, division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. "This data will give physicians insight into how to manage these difficult-to-treat infections and understand current treatment patterns in order to provide consensus on how best to care for patients."

Complicated skin and soft tissue infections account for almost 10 percent of all hospital admissions in the U.S. The most common types of cSSTIs are post-operative surgical site infections, which represent up to 25 percent of all hospital infections. Cellulitis and soft tissue abscesses are among the most common reasons for emergency department visits.

According to the National Institutes of Health, 111,000 people with diabetes are hospitalized with foot infections each year, and as many as 3.09 million adults will develop a diabetic foot infection in their lifetime.

The increased incidence of one of the most common resistant bacteria that are causing cSSTI, methicillin-resistant Staphylococcus aureus (MRSA), poses a significant challenge and burden to the U.S. health care system. Despite the high incidence of cSSTIs, a limited understanding remains and a wide variety of treatment options are used which often affect patient outcomes.

The emergence of resistant bacteria has created a need for new antibiotics and treatment strategies. As such, treatment choices made by physicians can significantly impact how patients with cSSTI respond to care.


'/>"/>

Contact: Amy Firsching
908-218-7583
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Source:Eurekalert

Related medicine news :

1. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
2. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
3. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
4. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
(Date:4/24/2017)... Lake City, UT (PRWEB) , ... April 24, 2017 , ... ... their efforts to encourage sustainability, innovate new strategies to reduce waste, and support renewable ... herbal remedy provider. They look to nature to find solutions for health issues, and ...
(Date:4/24/2017)... , ... April 24, 2017 , ... The California Dental ... in charitable dental services to 1,961 people during the April 22-23 event at the ... charge to Californians who experience barriers to care, CDA Cares educates the public and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... seeking public support to bring their novel lifesaving device for the everyday use ... with medical-grade sensors, specially designed to read a child’s vital signs, and detect ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... VANCOUVER , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) ... the Bloom Burton & Co. Healthcare Investor Conference 2017 at the ... Edward Wright , Chief Executive Officer of the Company is ... Company,s CFO, Richard Bear and the Chairman of the ... ...
Breaking Medicine Technology: